ADOCIA, the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today positive preliminary results from the extension part of the Phase 1b study of M1Pram (“ADO09”), a ready-to-use, fixed ratio coformulation of pramlintide (Symlin®, AstraZeneca), the only FDA-approved analog of amylin, and A21G human insulin analog (“M1”), a mealtime insulin with a similar time-action profile to human insulin and the main circulating metabolite of insulin glargine.